Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors

Todd M. Zimmerman*, Stephanie F. Williams

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


After extensive preclinical work, hematopoietic cellular therapy has recently entered a new era of clinical trials involving ex vivo cultured cells. The evolution of hematopoietic cell culture from clonogenic assays to large-scale static culture systems and bioreactors, and the identification and production of hematopoietic growth factors, have in part made this possible. In addition, murine models have demonstrated encouraging results with regard to the feasibility of infusing cultured cells, as well as to the potential efficacy. Several trials have recently been published utilizing ex vivo generated hematopoietic progenitors and myeloid progenitors, and are reviewed here. The field of clinical hematopoietic cellular therapy, while still in its infancy, is progressing rapidly, and promises to offer improved therapeutic options.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalCytokines, Cellular and Molecular Therapy
Issue number4
StatePublished - Dec 1998


  • CD34
  • Cellular therapy
  • Ex vivo expansion
  • Hematopoietic progenitors
  • Myeloid
  • Transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors'. Together they form a unique fingerprint.

Cite this